Cognitive Behavioral Therapy for Insomnia in People With Chronic Disease
Kognitive Verhaltenstherapie bei Insomnie bei Menschen mit chronischer Erkrankung
JAMA Internal Medicine · 01.11.2025 · 185 (11) · 1350
DOI: 10.1001/jamainternmed.2025.4610 ↗Auf einen Blick
67 RCTs mit 5232 Teilnehmenden zeigen: CBT-I verbesserte die Insomnie-Symptome und weitere Schlafparameter bei Erwachsenen mit chronischer Erkrankung.
Fragestellung
Wie wirksam und akzeptabel ist CBT-I bei Erwachsenen mit chronischer Erkrankung und Insomnie?
Methode
Systematische Übersichtsarbeit und Metaanalyse von RCTs; Datenbanken PsycINFO, Medline, Embase und CENTRAL bis 5. Juni 2025; Hedges g, Zufallseffekte, Subgruppenanalysen.
Ergebnisse
CBT-I verbesserte die Insomnie-Schwere (g = 0,98; 95 %-KI 0,81–1,16), die Schlafeffizienz (g = 0,77; 95 %-KI 0,63–0,91) und die Einschlaflatenz (g = 0,64; 95 %-KI 0,50–0,78). Dropout im Mittel 13,3 %.
Schlussfolgerung der Autor:innen
Die systematische Übersichtsarbeit und Metaanalyse zeigte eine starke Wirksamkeit und gute Akzeptanz von CBT-I bei chronischen Erkrankungen; die Effekte waren über Krankheitsgruppen ähnlich.
Kernaussagen
- Insomnie-Schwere verbessert: g = 0,98 (95 %-KI 0,81–1,16)
- Schlafeffizienz und Einschlaflatenz ebenfalls verbessert
- Treatment-related adverse effects were rare
Deutsche Zusammenfassung: KI-gestützt aus dem Original-Abstract erstellt; alle Zahlen wurden automatisch mit dem Original abgeglichen. Maßgeblich ist der Original-Abstract.
Kurz gefasst
Systematische Übersicht in der Zeitschrift JAMA Internal Medicine, erschienen am 01.11.2025. Verfasst von Amelia J Scott und 7 weiteren Autor:innen. Beteiligte Einrichtung: School of Psychological Sciences, Macquarie University, Sydney, New South Wales, Australia. Hauptthemen laut MEDLINE: Sleep Initiation and Maintenance Disorders, Cognitive Behavioral Therapy. Die Arbeit wurde bisher 43-mal zitiert (Crossref) und nennt 99 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.
Themen: Schlaf
Abstract (Originalsprache)
Importance Insomnia is highly prevalent among individuals with chronic disease (eg, chronic pain, cardiovascular disease, and cancer) and results in poorer disease outcomes and quality of life. Cognitive behavioral therapy for insomnia (CBT-I) is recommended as first-line treatment for insomnia. However, concerns remain about its applicability and efficacy in people with chronic disease.
Objective
To evaluate the nature, efficacy, and acceptability of CBT-I in adults with chronic disease, and to identify moderators of treatment outcomes. Data Sources Systematic searches were conducted in PsycINFO, Medline, Embase, and CENTRAL from database inception to June 5, 2025. Additional records were identified from reference lists of relevant reviews and studies. Study Selection Eligible studies were randomized clinical trials (RCTs) involving adults (aged ≥18 years) with chronic disease and insomnia. Studies using CBT-I with measured sleep outcomes were included. Data Extraction and Synthesis Two assessors extracted data from RCTs. Hedges g was used to calculate effect sizes, and random effects meta-analyses were conducted. Heterogeneity was assessed via I 2 . Subgroup analyses examined whether outcomes varied by delivery format, chronic condition type, or control group. Main Outcomes and Measures Primary outcomes included insomnia severity, sleep efficiency, and sleep onset latency. Secondary outcomes included treatment acceptability and adverse effects.
Results
Sixty-seven RCTs (5232 participants) met inclusion criteria, including chronic diseases such as cancer, chronic pain, irritable bowel syndrome, and stroke. CBT-I was associated with significantly improved outcomes for insomnia severity ( g = 0.98; 95% CI, 0.81-1.16) and moderate effect sizes regarding sleep efficiency ( g = 0.77; 95% CI, 0.63-0.91) and sleep onset latency ( g = 0.64; 95% CI, 0.50-0.78). Subgroup analyses revealed some sample, treatment, and methodological moderators (eg, longer treatment yielded better outcomes for sleep efficiency and sleep onset latency). Satisfaction with CBT-I was high, with a mean dropout rate of 13.3%. Treatment-related adverse effects were rare. Conclusions and Relevance This systematic review and meta-analysis showed that CBT-I demonstrated strong efficacy and acceptability in chronic disease populations, with moderate to large effect sizes that appear comparable to those in non–chronic disease populations. Efficacy of CBT-I was similar across a range of disease subgroups. Future research should explore the role and nature of treatment adaptations for specific populations and increase access to CBT-I in medical settings.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Autor:innen und Institutionen
- School of Psychological Sciences, Macquarie University, Sydney, New South Wales, Australia.
- CIRUS Centre for Sleep and Chronobiology, Woolcock Institute of Medical Research, Sydney, New South Wales, Australia.
Zitieren
APA
Scott, A. J., Correa, A. B., Bisby, M. A., Chandra, S. S., Rahimi, M., Christina, S., Heriseanu, A. I., & Dear, B. F. (2025). Cognitive Behavioral Therapy for Insomnia in People With Chronic Disease. JAMA Internal Medicine, 185(11), 1350. https://doi.org/10.1001/jamainternmed.2025.4610
Vancouver
Scott AJ, Correa AB, Bisby MA, Chandra SS, Rahimi M, Christina S, et al. Cognitive Behavioral Therapy for Insomnia in People With Chronic Disease. JAMA Internal Medicine. 2025;185(11):1350. doi:10.1001/jamainternmed.2025.4610
BibTeX
@article{Scott2025,
author = {Scott, Amelia J and Correa, Ashleigh B and Bisby, Madelyne A and Chandra, Shianika S and Rahimi, Matthew and Christina, Stefanny and Heriseanu, Andreea I and Dear, Blake F},
title = {Cognitive Behavioral Therapy for Insomnia in People With Chronic Disease},
journal = {JAMA Internal Medicine},
year = {2025},
volume = {185},
number = {11},
pages = {1350},
doi = {10.1001/jamainternmed.2025.4610}
}
EUVIMED